Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Trim from TD Cowen

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price decreased by TD Cowen from $482.00 to $354.00 in a research report report published on Friday morning,Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the stock. Bank of America reissued a “buy” rating and issued a $287.00 price objective (down from $460.00) on shares of Alnylam Pharmaceuticals in a research note on Friday. Oppenheimer decreased their target price on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. The Goldman Sachs Group dropped their price objective on Alnylam Pharmaceuticals from $536.00 to $320.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday. Finally, Raymond James Financial downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and decreased their price objective for the company from $420.00 to $315.00 in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $317.95.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $165.00 on Friday. Alnylam Pharmaceuticals has a 52 week low of $163.30 and a 52 week high of $479.79. The business’s 50-day moving average price is $236.49 and its 200 day moving average price is $286.19. The firm has a market cap of $22.10 billion, a price-to-earnings ratio of 8.57 and a beta of 0.43. The company has a quick ratio of 2.43, a current ratio of 2.48 and a debt-to-equity ratio of 0.18.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. The business’s revenue was up 16.7% on a year-over-year basis. During the same period last year, the business earned $2.90 EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals will post 6.58 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Legal & General Group Plc purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $278,321,000. Bank of New York Mellon Corp acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $148,128,000. Canada Pension Plan Investment Board bought a new position in Alnylam Pharmaceuticals during the second quarter valued at about $100,618,000. Korea Investment CORP bought a new stake in Alnylam Pharmaceuticals in the second quarter worth approximately $74,553,000. Finally, Wellington Management Group LLP lifted its holdings in Alnylam Pharmaceuticals by 9.0% during the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after purchasing an additional 174,482 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
• Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
• Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
• Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
• Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.